BioNJ’s First Two Entrepreneurship Fellows Launch Exciting Careers

BioNJ’s First Two Entrepreneurship Fellows Launch Exciting Careers 

Trenton, NJ (August 14, 2020) – BioNJ, the life sciences trade association for New Jersey, congratulates Irina Katz, PharmD, and Paul Oyefesobi, PharmD, RPh, the first two Fellows in BioNJ’s Entrepreneurship Fellowship Program, on successfully completing their fellowships and landing exciting positions in the industry.

Irina Katz just began a position as a Clinical Research Scientist at BioNJ Member Insmed and Paul Oeyfesobi will serve as a Senior Consultant at Guidehouse (formerly Navigant) — PwC’s Veritas-owned U.S. public sector business.

BioNJ’s Entrepreneurship Fellowship Program was created in 2018 to mentor, develop and train life sciences entrepreneurs in New Jersey to encourage the establishment and location of start-ups in the State. The Program is sponsored by New Jersey-based life sciences companies who offer hands-on, high value opportunities and experiences.

“We would like to thank our participating companies and Fellows for supporting the growth of New Jersey’s ecosystem,” said BioNJ President and CEO, Debbie Hart. “We are proud that our Fellows were able to participate in such a well-rounded experience — combining professional growth, personal development and endless networking opportunities.”

Sponsoring companies were Amicus Therapeutics, OncoSec Medical, Pfizer, Photocure, PTC Therapeutics and Rafael Pharma. 

“The BioNJ Fellowship was a unique, eye-opening experience, that allowed me to see multiple company cultures, various therapeutic areas and different functions within the biopharmaceutical industry,” said Katz. “You don’t know what you don’t know, and the BioNJ Fellowship was a great teacher showing me numerous possibilities and allowing me to test myself, my knowledge and my boundaries. BioNJ’s networking opportunities allowed me to unlock doors that I didn’t even know existed.”

“The BioNJ Fellowship program afforded me the opportunity to become well-versed and competent in various commercial functional areas in the biotech sector,” said Oyefesobi. “This rare opportunity provided the foundation to launch my career in a position where I will apply those same technical and soft skill sets developed during this Fellowship for life sciences clients. I strongly encourage anyone looking to step out of their comfort zone in the biotech space to consider the BioNJ Entrepreneurial Fellowship program.”

“OncoSec lucked out with Paul,” said Daniel O’Connor, President and CEO, OncoSec Medical. “During his time with us, Paul’s contributions were valuable and impactful to OncoSec’s mission.”

“The BioNJ Fellowship program is an excellent way for companies to access top scientific talent to enhance their workforces in the short-term, and evaluate long-term employment prospects in hands-on work settings,” said Monika Vnuk, M.D., Vice President, R&D Business Development, Pfizer. “While Irina was at Pfizer, she worked side by side with colleagues in business development, medical affairs and regulatory, contributing to evaluation of external opportunities and internal pipeline development. The rigorous interview process, conducted by BioNJ in concert with the Host Sponsoring Companies, identified a Fellow who had the right skills, work ethic, motivation and enthusiasm that made the experience a beneficial and valuable one for the Sponsor and the Fellow.”

To learn more about BioNJ’s Entrepreneurship Fellowship Program or to discuss how to develop a program tailored to meet your organization’s needs, contact

About BioNJ

BioNJ is the life sciences trade association for New Jersey with nearly 400 Member companies representing research-based life sciences organizations and stakeholders across the ecosystem from the largest biopharmaceutical companies to early stage start-ups. BioNJ is dedicated to ensuring a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit

Randi Bromberg
Vice President, Communications and Marketing
O) 609-890-3185
C) 609-955-1067